EFM
MCRB icon

E Fund Management’s Seres Therapeutics MCRB Stock Holding History

E Fund Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,405
Closed -$114K – 319
2023
Q3 		$114K Buy
2,405
+326
+16% +$24.9K 0.01% 279
2023
Q2 		$199K Buy
2,079
+1,400
+206% +$152K 0.02% 282
2023
Q1 		$77K Sell
679
-154
-18% -$16.7K 0.01% 326
2022
Q4 		$93K Buy
833
+129
+18% +$17.3K 0.01% 331
2022
Q3 		$90K Buy
+704
New +$72.1K 0.01% 329
2022
Q2 		– Sell
-744
Closed -$106K – 339
2022
Q1 		$106K Buy
744
+207
+39% +$31.8K ﹤0.01% 314
2021
Q4 		$89K Sell
537
-838
-61% -$133K ﹤0.01% 290
2021
Q3 		$191K Buy
+1,375
New +$269K 0.01% 234

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

E Fund Management's MCRB Position: Q4 2023 in Review

E Fund Management sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 2,405 shares — an estimated $114K sold.

E Fund Management first reported a position in MCRB in Q3 2021 and held it in 8 quarters. The position peaked at $199K in Q2 2023. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • E Fund Management reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • E Fund Management sold 2,405 Seres Therapeutics shares in Q4 2023, an estimated $114K.
  • E Fund Management first reported a position in Seres Therapeutics in Q3 2021 and held it in 8 quarters.
  • E Fund Management's Seres Therapeutics position peaked at $199K in Q2 2023.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on E Fund Management's 13F filing for Q4 2023, filed 7 Feb 2024.